2011 biotech of the year , page-4

I dont think that you need to convince the long term holders of the promise, but the market sentiment makes this stock illiquid most of the time. The roche report will be a company maker if all is good. Interesting that Cambridge has come to the forefront again. More interesting today was the volume traded and the buyers coming forward after no trading at all. 5 cents is a bloody joke. This should start to rally as it seems most of the 5 cent selloff seems to be finished. If this has real legs, the options are a steal at less than half a cent each especially if the SP starts getting toward the 16 cent mark. Go figure the market at the best of time but this company needs broker support which it obviously doesnt have after the selloff after the cap raising. and frankfurt mmmm dont think that has helped us one bit so far but who knows, be optomistic and hopefully the blind faith will be rewarded.